Prognostic Impact of Serum Pancreastatin Following Chemoembolization for Neuroendocrine Tumors

Strosberg, David S.; Schneider, Eric B.; Onesti, Jill K.; Saunders, Neil; Konda, Bhavana; Shah, Manisha H.; Dillhoff, Mary; Schmidt, Carl; Shirley, Lawrence A.

doi:10.1245/s10434-018-6741-x

Cited by 15 publications

(16 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the study by Strosberg et al [101], high level of pancreastatin, absence of previous resection of the primary tumour and higher percentage of liver involvement were associated with worse outcome. In the study by Hamiditabar et al [52], previous treatment with liver embolisation was found to be an independent prognostic factor for early disease progression (hazard ratio 2.7 [95% CI 1.215–6.034], p value 0.015) in multivariate analysis.…”

Section: Resultsmentioning

confidence: 99%

“…Information regarding prognostic factors was provided in 6 studies (5.9%) [52, 54, 61, 73, 101, 134].…”

Section: Resultsmentioning

confidence: 99%

“…Even though there is evidence supporting the role of a few poor prognostic factors (higher percentage of liver involvement [101], age, performance status and portal vein thrombosis [54, 73, 134]; there is still disagreement regarding the impact of extrahepatic disease [61, 134]), predictive factors able to identify patients more likely to benefit from liver embolisation are lacking [155]. Unfortunately, most studies included in this systematic review reported on a mixed population of patients with variable grade and primary tumours, and the effectivity of different forms of liver-directed therapies by grade or primary tumour site could not be explored.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Liver Embolisation for Patients with Neuroendocrine Neoplasms: Systematic Review

Kanabar

Barriuso

McNamara³

et al. 2020

Neuroendocrinology

View full text Add to dashboard Cite

Background: Liver embolisation is one of the treatment options available for patients diagnosed with neuro-endocrine neoplasms (NEN). It is still uncertain whether the benefits of the various types of embolisation treatments truly outweigh the complications in NENs. This systematic review assesses the available data relating to liver embolisation in patients with NENs. Methods: Eligible studies (identified using MED-LINE-PubMed) were those reporting data on NEN patients who had undergone any type of liver embolisation. The primary end points were best radiological response and symptomatic response; secondary end-points included progression-free survival (PFS), overall survival (OS) and toxicity. Results: Of 598 studies screened, 101 were eligible: 16 were prospective (15.8%). The eligible studies included a total of 5,545 NEN patients, with a median of 39 patients per study (range 5-214). Pooled rate of partial response was 36.6% (38.9% achieved stable disease) and 55.2% of patients had a symptomatic response to therapy when pooled data were analysed. The median PFS and OS were 18.4 months (95% CI 15.5-21.2) and 40.7 months (95% CI 35.2-46.2) respectively. The most common toxicities were found to be abdominal pain (48.8%) and nausea (48.1%). Outcome did not significantly vary depending on the type of embolisation performed. Conclusion: Liver embolisation provides adequate symptom relief for patients with carcinoid syndrome and is also able to reach partial response in a significant proportion of patients and a reasonable PFS. Quality of studies was limited, highlighting the need of further prospective studies to confirm the most suitable form of liver embolisation in NENs.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Information regarding prognostic factors was provided in 6 studies (5.9%) [52, 54, 61, 73, 101, 134].…”

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Liver Embolisation for Patients with Neuroendocrine Neoplasms: Systematic Review

Kanabar

Barriuso

McNamara³

et al. 2020

Neuroendocrinology

View full text Add to dashboard Cite

show abstract

“…The importance of neuroendocrine liver metastases (NELM) in the survival of patients with advanced panNENs is represented not only by the fact that presence of liver metastases is associated with worse survival [ 11 , 70 , 155 , 162 , 337 , 338 , 339 , 340 , 341 ], but also by a significant correlation between the higher tumor burden of NELM and worse outcomes with PRRT [ 59 , 62 , 186 , 213 ], SSA [ 173 , 174 , 177 , 179 , 225 ], liver-directed therapy [ 342 ], and chemotherapy [ 321 ] ( Table 5 ). Several studies have reported the efficacy of liver-directed therapies including TACE/TAE and radio-embolization using 90 Y-labeled microspheres (selective internal radiotherapy [SIRT]), in controlling focal progression of NELM [ 69 , 70 , 71 , 72 , 74 , 341 , 343 ], as well as in controlling symptoms due to the liver metastases or hormone excess state of a F-panNENs [ 9 , 39 , 70 , 71 , 74 , 341 , 344 ].…”

Section: Predictive Factors For Response To Liver-directed Therapies ...mentioning

confidence: 99%

Predictive Factors for Resistant Disease with Medical/Radiologic/Liver-Directed Anti-Tumor Treatments in Patients with Advanced Pancreatic Neuroendocrine Neoplasms: Recent Advances and Controversies

Lee

Ramos-Álvarez

Jensen

2022

Cancers

View full text Add to dashboard Cite

Purpose: Recent advances in the diagnosis, management and nonsurgical treatment of patients with advanced pancreatic neuroendocrine neoplasms (panNENs) have led to an emerging need for sensitive and useful prognostic factors for predicting responses/survival. Areas covered: The predictive value of a number of reported prognostic factors including clinically-related factors (clinical/laboratory/imaging/treatment-related factors), pathological factors (histological/classification/grading), and molecular factors, on therapeutic outcomes of anti-tumor medical therapies with molecular targeting agents (everolimus/sunitinib/somatostatin analogues), chemotherapy, radiological therapy with peptide receptor radionuclide therapy, or liver-directed therapies (embolization/chemoembolization/radio-embolization (SIRTs)) are reviewed. Recent findings in each of these areas, as well as remaining controversies and uncertainties, are discussed in detail, particularly from the viewpoint of treatment sequencing. Conclusions: The recent increase in the number of available therapeutic agents for the nonsurgical treatment of patients with advanced panNENs have raised the importance of prognostic factors predictive for therapeutic outcomes of each treatment option. The establishment of sensitive and useful prognostic markers will have a significant impact on optimal treatment selection, as well as in tailoring the therapeutic sequence, and for maximizing the survival benefit of each individual patient. In the paper, the progress in this area, as well as the controversies/uncertainties, are reviewed.

show abstract

“…Previous studies have suggested that patients with severe symptoms, lower liver tumor burden on imaging examinations or lower level of serum pancreastatin may potentially bene t from TAE/ TACE [6][7][8][9]. However, the prediction tool for therapeutic evaluation of TAE/ TACE is still unclear and optimal candidates for this procedure remain undetermined.…”

Section: Introductionmentioning

confidence: 99%

Prediction Role of Baseline Digital Substraction Angiography in GEP Neuroendocrine Liver Metastases Treated with TAE/ TACE

et al. 2021

Preprint

View full text Add to dashboard Cite

Aim Transarterial embolization (TAE) or transarterial chemoembolization (TACE) is an important treatment approach for unresectable liver metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The prediction tool for therapeutic evaluation is still unclear. This study was performed to assess the prediction role of baseline digital substraction angiography (DSA) in synchronous liver metastatic GEP-NETs treated with TAE/ TACE. Methods Twenty-two patients with synchronous unresectable liver metastatic GEP-NETs (G1/2) and treated with TAE/ TACE were retrospectively enrolled. Clinical characteristics, baseline DSA and computed tomography (CT) information were collected. Results Totally, the overall response rate of TAE/ TACE on liver metastasis was 45.5%. The average baseline CT ratio (the density of the target lesion / the density of abdominal aorta during arterial phase) between responsive group and nonresponsive group were not statistically different (0.30±0.06 versus 0.36±0.11, P=0.149). Whereas, the average baseline DSA ratio (the density of target lesion / the density of liver background on DSA imaging before TAE/ TACE) of responsive group was significantly lower compared with that of nonresponsive group (0.57±0.13 versus 0.70±0.15, P=0.037). Patients with a DSA ratio ≤0.64 were more responsive to TAE/ TACE than those with a DSA ratio ༞0.64 (58.3% versus 30%). Univariate and multivariate analysis indicated that patients with lower hepatic tumor burden had longer PFS. Conclusions Baseline DSA ratio is a simple and potentially useful method to predict therapeutic effect of TAE/ TACE in liver metastases from GEP-NETs. And patients with lower hepatic tumor burden might indicate better prognosis. Prospective large-scale study is warranted.

show abstract

Prognostic Impact of Serum Pancreastatin Following Chemoembolization for Neuroendocrine Tumors

Cited by 15 publications

References 19 publications

Liver Embolisation for Patients with Neuroendocrine Neoplasms: Systematic Review

Liver Embolisation for Patients with Neuroendocrine Neoplasms: Systematic Review

Predictive Factors for Resistant Disease with Medical/Radiologic/Liver-Directed Anti-Tumor Treatments in Patients with Advanced Pancreatic Neuroendocrine Neoplasms: Recent Advances and Controversies

Prediction Role of Baseline Digital Substraction Angiography in GEP Neuroendocrine Liver Metastases Treated with TAE/ TACE

Contact Info

Product

Resources

About